Abstract
The recently published Scandinavian Simvastatin Survival Study showed that long-term treatment with simvastatin, in patients with ischaemic heart disease and serum cholesterol levels between 5.5 and 8.0 mmol/l, improved survival. The present study was conducted in order to evaluate whether patients with ischaemic heart disease awaiting coronary revascularisation are aware of their serum cholesterol levels and whether raised levels are being treated adequately. One hundred consecutive patients admitted from our waiting list for elective coronary artery bypass grafting, with or without valve replacement, were included in the study. The patients were asked whether they had a history of raised serum cholesterol and, if so, how this was being treated. Fasting serum cholesterol levels were subsequently taken in the morning before surgery. Forty-six patients gave a positive history of raised blood cholesterol levels; 25 of these were on cholesterol-lowering medication at the time of admission, 15 were on a lipid-lowering diet and six were not being treated. Thirty-one (67%) of these 46 patients had a serum cholesterol of more than 5.5 mmol/l, compared with 30 (56%) of the 54 patients without a positive history of hypercholesterolaemia, and 61% of the total 100 patients. These data suggest that an inadequate number of patients awaiting coronary artery bypass grafting are aware of their cholesterol status. The management of hypercholesterolaemia among these patients could be improved.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Azen S. P., Mack W. J., Cashin-Hemphill L., LaBree L., Shircore A. M., Selzer R. H., Blankenhorn D. H., Hodis H. N. Progression of coronary artery disease predicts clinical coronary events. Long-term follow-up from the Cholesterol Lowering Atherosclerosis Study. Circulation. 1996 Jan 1;93(1):34–41. doi: 10.1161/01.cir.93.1.34. [DOI] [PubMed] [Google Scholar]
- Buchwald H., Varco R. L., Matts J. P., Long J. M., Fitch L. L., Campbell G. S., Pearce M. B., Yellin A. E., Edmiston W. A., Smink R. D., Jr Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia. Report of the Program on the Surgical Control of the Hyperlipidemias (POSCH) N Engl J Med. 1990 Oct 4;323(14):946–955. doi: 10.1056/NEJM199010043231404. [DOI] [PubMed] [Google Scholar]
- Carlson L. A., Danielson M., Ekberg I., Klintemar B., Rosenhamer G. Reduction of myocardial reinfarction by the combined treatment with clofibrate and nicotinic acid. Atherosclerosis. 1977 Sep;28(1):81–86. doi: 10.1016/0021-9150(77)90201-5. [DOI] [PubMed] [Google Scholar]
- Guidelines and indications for coronary artery bypass graft surgery. A report of the American College of Cardiology/American Heart Association Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular Procedures (Subcommittee on Coronary Artery Bypass Graft Surgery). J Am Coll Cardiol. 1991 Mar 1;17(3):543–589. [PubMed] [Google Scholar]
- Hiratzka L. F. Secondary prevention of atherosclerosis: emphasizing risk factor management to patients. Ann Thorac Surg. 1995 Jul;60(1):1–1. doi: 10.1016/s0003-4975(95)00382-7. [DOI] [PubMed] [Google Scholar]
- LaRosa J. C., Hunninghake D., Bush D., Criqui M. H., Getz G. S., Gotto A. M., Jr, Grundy S. M., Rakita L., Robertson R. M., Weisfeldt M. L. The cholesterol facts. A summary of the evidence relating dietary fats, serum cholesterol, and coronary heart disease. A joint statement by the American Heart Association and the National Heart, Lung, and Blood Institute. The Task Force on Cholesterol Issues, American Heart Association. Circulation. 1990 May;81(5):1721–1733. doi: 10.1161/01.cir.81.5.1721. [DOI] [PubMed] [Google Scholar]